Last reviewed · How we verify

Celebrex plus Metformin — Competitive Intelligence Brief

Celebrex plus Metformin (Celebrex plus Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 inhibitor + biguanide antidiabetic. Area: Diabetes, Rheumatology, Metabolic Disease.

phase 3 COX-2 inhibitor + biguanide antidiabetic COX-2 and mitochondrial glycerophosphate dehydrogenase Diabetes, Rheumatology, Metabolic Disease Small molecule Live · refreshed every 30 min

Target snapshot

Celebrex plus Metformin (Celebrex plus Metformin) — Guangxi Medical University. This combination uses celecoxib (a COX-2 inhibitor) to reduce inflammation and metformin (a biguanide) to improve insulin sensitivity and glucose metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Celebrex plus Metformin TARGET Celebrex plus Metformin Guangxi Medical University phase 3 COX-2 inhibitor + biguanide antidiabetic COX-2 and mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 inhibitor + biguanide antidiabetic class)

  1. Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celebrex plus Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/celebrex-plus-metformin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: